Overview

Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting

Status:
Recruiting

Trial end date:
2022-05-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the feasibility of identifying, recruiting and randomizing a large sample of Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine or standard-dose quadrivalent influenza vaccine in the 2021/2022 influenza season in a registry-based setting using Danish nationwide registries for all data collection including baseline information and outcome assessment.

Phase:

Phase 2

Details

Lead Sponsor:

Tor Biering-Sørensen

Collaborator:

Sanofi Pasteur, a Sanofi Company

Treatments:

Vaccines